(−)-CGP 12177 Causes Cardiostimulation and Binds to Cardiac Putative β4-Adrenoceptors in Both Wild-Type and β3-Adrenoceptor Knockout Mice

  1. Alberto J. Kaumann1,
  2. Frédéric Preitner2,
  3. Doreen Sarsero3,
  4. Peter Molenaar3,
  5. Jean-Pierre Revelli2 and
  6. Jean Paul Giacobino2
  1. 1The Babraham Institute, Cambridge CB2 4AT, UK (A.K.),2Département de Biochimie Médicale, Centre Médical Universitaire, CH-1211 Genève 4, Switzerland (F.P., J.P.R., J.P.G.), and 3Department of Pharmacology, The University of Melbourne, Victoria 3052, Australia (D.S., P.M.)
     
    Next Section

    Abstract

    Some blockers of β1- and β2-adrenoceptors cause cardiostimulant effects through an atypical β-adrenoceptor (putative β4-adrenoceptor) that resembles the β3-adrenoceptor. It is likely but not proven that the putative β4-adrenoceptor is genetically distinct from the β3-adrenoceptor. We therefore investigated whether or not the cardiac atypical β-adrenoceptor could mediate agonist effects in mice lacking a functional β3-adrenoceptor gene (β3KO). (−)-CGP 12177, a β1- and β2-adrenoceptor blocker that causes agonist effects through both β3-adrenoceptors and cardiac putative β4-adrenoceptors, caused cardiostimulant effects that were not different in atria from wild-type (WT) mice and β3KO mice. The effects of (−)-CGP 12177 were resistant to blockade by (−)-propranolol (200 nm) but were blocked by (−)-bupranolol (1 μm) with an equilibrium dissociation constant of 15 nm in WT and 17 nmin β3KO. (−)-[3H]CGP 12177 labeled a similar density of the putative β4-adrenoceptor in ventricular membranes from the hearts of both WT (Bmax = 52 fmol/mg protein) and β3KO (Bmax = 53 fmol/mg protein) mice. The affinity of (−)-[3H]CGP 12177 for the cardiac putative β4-adrenoceptor was not different between WT (Kd = 46 nm) and β3KO (Kd= 40 nm). These results provide definitive evidence that the cardiac putative β4-adrenoceptor is distinct from the β3-adrenoceptor.

    The existence of a third cardiostimulatory β-adrenoceptor, in addition to coexisting cardiac β1- and β2-adrenoceptors, was proposed in 1989 (Kaumann, 1989). The receptor has been found in the hearts of all mammalian species investigated so far, including mouse and man (Kaumann, 1997). The receptor mediates increases in heart rate and force caused by nonconventional partial agonists, which are compounds that are also high affinity blockers of β1- and β2-adrenoceptors (Kaumann, 1989). The cardiostimulant effects of nonconventional partial agonists are relatively resistant to blockade by the β1/β2-adrenoceptor blocker (−)-propranolol but are antagonized by the β1/β2-adrenoceptor blocker (−)-bupranolol, albeit with lower affinity than for β1- and β2-adrenoceptors (Walter et al., 1984; Kaumann, 1989, 1996; Kaumann and Molenaar, 1996).

    Certain properties of the third cardiostimulant β-adrenoceptor resemble those of β3-adrenoceptors (Kaumann, 1989) but differences have also been pointed out recently (Kaumann, 1997; Kaumann and Molenaar, 1997). For example, after it was published that (−)-bupranolol blocked the effects of the third cardiostimulant β-adrenoceptor (Kaumann, 1989), reports started to appear showing that bupranolol also blocks the lipolytic effects of β3-adrenoceptor-selective agonists mediated through native β3-adrenoceptors in adipocyte tissues (Langin et al., 1991; Galitzky et al., 1997) and adenylyl cyclase stimulation in cells transfected with the β3-adrenoceptor (Blin et al., 1994;Strosberg and Pietri-Rouxel, 1996). Furthermore, nonconventional partial agonists have agonist effects, mediated through native (Granneman et al., 1991; Langin et al., 1991;Lönnqvist et al., 1993; Kaumann and Molenaar, 1996) and recombinant (Granneman et al., 1991, 1993; Blin et al., 1994; Molenaar et al., 1997a) β3-adrenoceptors.

    The introduction of β3-adrenoceptor-selective agonists [see Arch and Kaumann (1993) for review] has provided a tool to test the hypothesis of whether or not the cardiostimulatory atypical β-adrenoceptor is a β3-adrenoceptor. β3-adrenoceptor-selective agonists do not cause tachycardia in rat hearts in vivo through the atypical β-adrenoceptor (Malinowska and Schlicker, 1996) or are completely devoid of stimulant or depressant chronotropic effects in vitro (Kaumann and Molenaar, 1996). Moreover, β3-adrenoceptor-selective agonists fail to cause positive inotropic effects and do not block the cardiostimulation evoked by the nonconventional partial agonist (−)-CGP 12177 in rat (Kaumann and Molenaar, 1996) and human (Sarsero et al., 1996; Molenaar et al., 1997b) cardiac preparations. A β3-adrenoceptor-selective antagonist, SR 59230A, caused only marginal blockade of the cardiostimulant effects of (−)-CGP 12177 (Kaumann and Molenaar, 1996).

    The failure of β3-adrenoceptor-selective ligands to affect cardiostimulant responses to nonconventional partial agonists suggested that β3-adrenoceptors were not involved in these effects (Kaumann and Molenaar, 1996; Malinowska and Schlicker, 1996). It has therefore been proposed that a putative β4-adrenoceptor mediates the cardiostimulant effects of nonconventional partial agonists and other ligands (Kaumann, 1997; Kaumann and Molenaar, 1997). A binding assay for the cardiac putative β4-adrenoceptor has recently been introduced using (−)-[3H]CGP 12177 (Molenaaret al., 1997b; Sarsero et al., 1997, 1998a). As expected, nonconventional partial agonists and (−)-bupranolol compete for binding with affinities expected from their stimulant and blocking potencies obtained from functional studies. There is evidence that the catecholamine (−)-isoproterenol causes cardiostimulant effects, presumably through the putative β4-adrenoceptor. In vivo,Wheeldonet al. (1993) showed in man that (−)-isoproterenol could cause positive inotropic and lusitropic effects by stimulation of a β-adrenoceptor other than a β1- or β2-adrenoceptor, which we also argued was the putative β4-adrenoceptor (Molenaar et al., 1997b; Sarsero et al., 1998). Functional evidence with the endogenous catecholamines is still pending. However, as expected for a β-adrenoceptor, the catecholamines (−)-norepinephrine and (−)-epinephrine bind to the rat atrial putative β4-adrenoceptor with affinity similar to that of (−)-isoproterenol in a stereoselective manner (Sarsero et al., 1998). The putative β4-adrenoceptor does not bind 5-hydroxytryptamine, histamine, atropine, or the α-adrenoceptor antagonist phentolamine (Sarsero et al., 1998a) at concentrations of these drugs that saturate their corresponding receptors. In agreement with functional studies, β3-adrenoceptor-selective agonists and antagonists fail to compete for binding.

    Cardiodepressant effects of β3-adrenoceptor-selective agonists have been reported in human right interventricular septal biopsies from transplanted patients (Gauthier et al., 1996). The effects of one of these agonists, BRL 37344, was blocked by (−)-bupranolol (Gauthier et al., 1996). It has been claimed that nanomolar concentrations of β3-adrenoceptor-selective agonists decrease contractile force and shorten action potential duration, and that the cardiodepression is blunted by pertussis toxin, suggesting coupling of the β3-adrenoceptor to Gi protein (Gauthier et al., 1996). Further support was obtained by the detection of β3-adrenoceptor mRNA in human ventricular myocytes (Gauthier et al. 1996), as found previously in human heart tissues (Krief et al., 1993; Berkowitz et al., 1995). Gauthier et al. (1996) suggested that β3-adrenoceptors may worsen heart failure by mediating cardiodepressant effects of norepinephrine (Gauthier et al., 1996). However, others have failed to observe significant cardio-depressant effects using micromolar concentrations of β3-adrenoceptor-selective agonists in human ventricular trabeculae (Kaumann and Molenaar, 1997; Molenaar et al., 1997b) and cardiomyocytes (Harding, 1997). In contrast to the claimed coupling of human ventricular β3-adrenoceptors to Giprotein (Gauthier et al., 1996), evidence suggests that the cardiac putative β4-adrenoceptor is coupled to the Gs protein/adenylyl cyclase pathway (Kaumann, 1997; Kaumann and Lynham, 1997; Kaumann and Molenaar, 1997; Kaumannet al., 1997). As expected from receptor coupling to Gs protein, activation of the putative β4-adrenoceptor increases cardiac cAMP levels and stimulates cAMP-dependent protein kinase in cardiac preparations of rat (Kaumann and Lynham, 1997; Kaumann et al., 1997) and human atrium (Sarsero et al., 1998b).

    Taken together, the above evidence suggests that the proposed cardiac putative β4-adrenoceptor differs from β3-adrenoceptors. However, an alternative explanation has been forwarded. It has been suggested (Arch, 1997) that the cardiac atypical β-adrenoceptor is a β3-adrenoceptor that adopts a conformation or associates with G proteins differently from transfected cells (Kenakin, 1995), so that it is stimulated by nonconventional partial agonists but not by β3-adrenoceptor-selective agonists. To obtain an unambiguous answer to the question of whether the atypical cardiostimulant β-adrenoceptor is merely a β3-adrenoceptor or a novel putative β4-adrenoceptor, we decided to use cardiac tissues from a mouse with targeted disruption of its β3-adrenoceptor [i.e., β3KO (Susulic et al., 1995; Revelliet al., 1997)]. We studied the positive chronotropic and inotropic effects of the nonconventional partial agonist (−)-CGP 12177 on right and left atria from WT mice and investigated whether or not these effects could be produced in atria from β3KO mice. We measured atypical β-adrenoceptor binding sites, labeled with (−)-[3H]CGP 12177 in ventricular membranes of the two groups of mice. We also used Northern blots to assess whether β3-adrenoceptor mRNA could be detected in mouse heart. All results are consistent with the existence of a cardiac putative β4-adrenoceptor that is distinct from the β3-adrenoceptor.

    Previous SectionNext Section

    Materials and Methods

    β3KO mice.

    The targeted disruption (i.e., cloning) of the 129 Sv mouse β3-adrenoceptor gene, the construction of the targeting plasmid, the electroporation, the injection of the ES cell line carrying the disrupted β3-adrenoceptor into C57BL/6J blastocysts, and the screening of the progeny have been described in detail elsewhere (Revelli et al., 1997). Five- to seven-week-old homozygous WT and β3KO and female mice were obtained from established colonies.

    Southern blot genotyping.

    The identification of the WT or homozygous β3KO mice was performed by Southern blot analysis on BglII-digested tail DNA using ourSfiI-BglII external probe. The BglII fragment of the recombinant allele encompasses the neomycin resistance gene driven by a PGK promoter (PGK-NEO) and is therefore larger than the WT fragment (4.7 and 3.4 kb, respectively) (Revelli et al., 1997).

    Northern blots.

    Experiments were performed on tissues from female mice housed in groups of six at a temperature of 24° and fedad libitum a standard laboratory chow diet. Interscapular BAT and heart ventricles were dissected and carefully trimmed from contaminating white adipose tissue. Total RNA was isolated using the Trizol technique (GIBCO BRL, New York, NY) and poly(A)+ RNA using an mRNA purification kit (Pharmacia Biotech, Uppsala, Sweden). Twelve micrograms of total RNA or 10 μg of poly(A)+ RNA was electrophoresed in a 1.2% agarose gel containing formaldehyde, as described by Lehrachet al. (1977), and transferred to Electran Nylon Blotting membranes (BDH Laboratory Supplies, Poole, UK) by vacuum blotting. The β3-adrenoceptor probe used was that previously described (Revelli et al., 1992). It was labeled by random priming with [α-32P]dCTP (Amersham, Buckinghamshire, UK) to a specific radioactivity of approximately 1 × 109 dpm/μg DNA. Northern blots were hybridized for 2 hr at 65° in QuickHyb solution (Stratagene, La Jolla, CA), and washed in a solution of 2× standard saline citrate (2× = 300 mm NaCl, 30 mm sodium citrate, pH 7.0)/0.1% sodium dodecyl sulfate at 50° twice for 5 min and in 0.1× standard saline citrate/0.1% sodium dodecyl sulfate at 50° for 5 min. Blots were exposed to Hyperfilm electrochemiluminescence films (Amersham, Buckinghamshire, UK) at −80° with intensifying screens. Size estimates for the RNA species were established by comparison with an RNA Ladder (GIBCO BRL).

    Isolated atria.

    Female mice aged 5–7 weeks (weight 17–23 g) were killed by dislocation of the neck in accordance with Home Office (UK) procedures and the hearts immediately taken out and placed in oxygenated solution at room temperature containing 106 mm NaCl, 5 mm KCl, 2.25 mmCaCl2, 0.5mmMgSO4, 1 mmNa2HPO4, 34 mmNaHCO3, 5 mm fumarate, 5 mm pyruvate, 5 mm glutamate, 10 mmglucose, and 0.04 mm EDTA, equilibrated with 95% O2 and 5% CO2; the water was deionized and double distilled. Right atria and left atria were carefully dissected at room temperature. After cutting away valves and great vessels, the ventricles were freeze-clamped in liquid nitrogen. The atria were set up in pairs at 37° in a 50-ml organ bath (Blinks, 1965) containing the above solution; one tissue was from a WT mouse and the other from a β3KO mouse. The tissues were attached to Swema 4–45 strain gauge transducers and force was recorded on a Watanabe polygraph. Spontaneously beating right atria were stretched enough to count rate from fast-speed tracings. Left atria were paced at 2 Hz with square-wave pulses of 5 msec duration and of just over threshold voltage. After determination of a length-tension curve, the length of each strip was set to obtain 50% of the resting tension associated with maximum developed force. A single cumulative concentration-effect curve to (−)-CGP 12177 was determined on right atria in the absence or presence of (−)-propranolol (200 nm) or (−)-bupranolol (1 μm). These antagonists were present for at least 60 min before a curve was begun. Positive inotropic responses to (−)-CGP 12177 in mouse left atria are smaller than positive chronotropic responses in mouse right atria. We have previously observed that IBMX potentiates the responses to (−)-CGP 12177 on rat atria, in line with a cAMP-dependent pathway (Kaumann and Lynham 1997), so to obtain robust positive inotropic responses to (−)-CGP 12177, we incubated left atria with IBMX (6 μm). When an equilibrium response to IBMX was observed, a single concentration of (−)-CGP 12177 was added as shown in the representative experiment of Fig. 2. The experiments were concluded by the administration of a β-adrenoceptor-saturating concentration of (−)-isoproterenol (400 μm) and in the case of left atria, after an equilibrium response to (−)-isoproterenol was established, by raising the CaCl2 concentration to 6.7 mm. −Log EC50 values were estimated from each concentration-effect curve of (−)-CGP 12177 on right atrium. The equilibrium dissociation constantKB for the (−)-bupranolol-β4-adrenoceptor complex was estimated from the concentration-ratio of (−)-CGP 12177 using EC50 values in the presence and absence of (−)-bupranolol. The error of the concentration-ratio was estimated as described (Kaumann, 1990).

    Figure 2
    View larger version:
    Figure 2

    Comparison of the positive inotropic effects of (−)-CGP 12177 on a left atrium from a WT mouse and a β3KO mouse set up in the same organ bath. Fast and slow speed tracings are shown. Experiments were carried out in the presence of (−)-propranolol (200 nm). Top, The effects of IBMX and (−)-CGP 12177 in the presence of BMX. Bottom, The time course of the effects of (−)-CGP 12177 followed by the effects of (−)-isoproterenol added 40 min after the administration of (−)-CGP 12177. The experiment was terminated by raising the CaCl2 concentration to 6.7 mm.

    Binding assay.

    Binding was carried out as described (Sarseroet al., 1998). During dissection of the hearts of WT and β3KO mice, the ventricles were cleaned of pericardium, valves, and blood vessels and quickly freeze-clamped and stored at −70° until use. The ventricles were homogenized in ice-cold Tris/Mg2+ assay buffer containing 50 mm Tris·HCl, 5 mm EGTA, 1 mmEDTA, 4 mm MgCl2, 1 mmascorbic acid, and 0.5 mm phenylmethylsulfonyl fluoride, pH 7.4, centrifuged for 5 min at 175 × g at 4°. The supernatant was centrifuged for 15 min at 50,000 × gat 4° and the pellet resuspended in 15 volumes of ice-cold assay buffer. For binding to putative β4-adrenoceptors, 1–200 nm(−)-[3H]CGP 12177 (specific activity 44.5 Ci/mmole) was used in the presence of 500 nm(−)-propranolol and 100 μm GTP with 20 μm(−)-CGP 12177 to define nonspecific binding. Assays were carried out at 37° for 120 min. Protein was determined using bovine serum albumin as standard (Lowry et al., 1951). The results were analyzed by assuming a single population of sites by nonlinear curve fitting using PRISM (GraphPAD Software, San Diego, CA).

    Drugs.

    (−)-CGP 12177 was a gift from SmithKline Beecham (Harlow, Essex, UK) and (−)-bupranolol was a gift from Sanol (Monheim, Germany). (−)-[3H]CGP 12177 was purchased from Dupont (Boston, MA) and (−)-propranolol and (−)-isoproterenol were purchased from Sigma (St Louis, MO).

    Statistics.

    All data are expressed as mean ± standard error. Significance between differences was assessed with Student’st test at p < 0.05.

    Previous SectionNext Section

    Results and Discussion

    The genotypes of mice used in this study were validated in the Southern blots of Fig. 1a. The potential expression of the β3-adrenoceptor gene on WT mouse heart ventricle was assessed by Northern blot analysis using total or poly(A)+ RNA. As shown in Fig. 1b, no β3-adrenoceptor signal could be detected in total RNA of heart ventricles of WT mice, even on a 3-day-exposed autoradiogram. To increase the sensitivity of detection of β3-adrenoceptor mRNA, Northern blot analysis was performed on 10 μg of poly(A)+ of WT heart ventricle. No signal could be seen after an 8-hr exposure of the film (data not shown). However, on a 3-day-exposed autoradiogram, a faint band appeared (not shown). This band was estimated to represent no more than 1/1000 of that found in BAT. This finding suggests two interpretations: the ventricles express β3-adrenoceptors at very low level or, alternatively, were contaminated with adipocytes. In any case, heart ventricles of β3KO provide a model of a tissue devoid of β3-adrenoceptors. Fig. 1b demonstrates that the BAT of β3KO mice does not express β3-adrenoceptor mRNA whereas BAT of WT does at the sizes of the major transcripts (i.e., 2.3, 2.7 and 3.1 kb), confirming previous results (Revelli et al., 1997).

    Figure 1
    View larger version:
    Figure 1

    a, Southern blot of WT or homozygous β3KO mouse tail genomic DNA digested withBglII and hybridized with theSfiI-BglII external probe, showing the 3.4 kb WT and the 4.7 kb recombinant allele. Lanes,pools of the DNAs obtained from two mice of the same genotype. b, Northern blot detection of the β3-adrenoceptor mRNA in ventricle (HEART) total RNAs of WT mice. Expression of β3-adrenoceptor mRNA is also shown in BAT total RNAs of β3KO or WT mice. The radiogram was exposed 8 hr. The positions of the molecular size markers are indicated in kilobase pair(s).

    Human and rat β3-adrenoceptor genes have been shown to contain at least three and two exons, respectively (Giacobino, 1995). The first exon encodes the major part of the β3-adrenoceptor coding sequence, and it has been postulated that, in rodent as in man, alternative splicing of the β3-adrenoceptor primary transcripts could generate isoforms with different carboxyl termini (Lelias et al., 1993; Giacobino, 1995). In our targeting plasmid, the β3-adrenoceptor was interrupted by the PGK-NEO cassette in the first exon XhoI site, which is far upstream of the splice signal. Therefore, in our targeted disruption of the β3-adrenoceptor by homologous recombination (Revelli et al., 1997), there is no possibility of a splice variant bypassing the interruption of the gene.

    In contrast to the reported lack of β3-adrenoceptor-mediated effects in β3KO mice (Susulic et al., 1995;Revelli et al., 1997), marked cardiostimulation by (−)-CGP 12177 was observed in atria from both WT and β3KO mice. Basal contractile force was similar in atria from WT (0.52 ± 0.18 mN, n = 7) and β3KO mice (0.54 ± 0.12 mN,n = 11). The effects of (−)-CGP 12177 were investigated in the presence of 200 nm (−)-propranolol and 6 μm IBMX. IBMX caused a small increase in contractile force that was different in WT (24 ± 8%) and β3KO mice (17 ± 6%) but statistically insignificant. A representative experiment is shown in Fig.2. (−)-CGP 12177 (1 μm) increased contractile force further in atria from both WT and β3KO mice. The effects of (−)-CGP 12177 (0.1 and 1 μm, respectively) did not differ significantly between the two groups of mice (Figs. 3). The effects of (−)-CGP 12177 were prevented by 1 μm(−)-bupranolol in atria from three β3KO mice (Fig. 3) and from two WT mice (not shown).

    Figure 3
    View larger version:
    Figure 3

    Comparison of the positive inotropic effects of (−)-CGP 12177 and blockade by (−)-bupranolol (1 μm, BU, •, n = 3) on left atria from WT (▵,n = 6) and β3KO (○,n = 6) mice. Experiments carried out in the presence of (−)-propranolol (200 nm) and IBMX (6 μm).

    (−)-CGP 12177 increased beating rate in right atria of both WT and β3KO mice to a similar extent (Fig.4). Neither the potency (Table1) nor the maximal effects (Figs. 4-6) of (−)-CGP 12177 differed significantly in atria from both groups of mice. (−)-Propranolol (200 nm) did not significantly affect the potency (Table 1) or maximal effects of (−)-CGP 12177 on atria from WT and β3KO mice (Fig.5). In contrast, (−)-bupranolol (1 μm) blocked surmountably the effects of (−)-CGP 12177 and shifted its concentration-effect curve to a similar extent in atria from WT and β3KO mice (Table 1, Fig.6). A pKb of around 7.8 was estimated for (−)-bupranolol in the right atria of both groups of mice (Table 1).

    Figure 4
    View larger version:
    Figure 4

    Comparison of the positive chronotropic effects of (−)-CGP 12177 and (−)-isoproterenol on spontaneously beating right atria from WT (○, n = 4) and β3KO (▵, n = 4) mice.

    View this table:
    Table 1

    Comparison of chronotropic potency of (−)-CGP 12177 and blocking potency of (−)-bupranolol, lack of blockade by (−)-propranolol.

    Figure 5
    View larger version:
    Figure 5

    Lack of blockade by (−)-propranolol (200 nm, open and closed squares) of the positive chronotropic effects of (−)-CGP 12177 on spontaneously beating right atria from WT (▵, left) and β3KO (○,right). n = 4 atria for each curve.

    Figure 6
    View larger version:
    Figure 6

    Blockade by (−)-bupranolol (1 μm, closed symbols) of the positive chronotropic effects of (−)-CGP 12177 on spontaneously beating right atria from WT (□, left) and β3KO (○, right) mice.n = 4 atria for each curve.

    The unperturbed cardiostimulation by (−)-CGP 12177 in β3KO, compared with WT, suggests that the density of the putative β4-adrenoceptor population was the same in the two groups of mice. Fig.7 shows that this was the case. (−)-[3H]CGP 12177-labeled saturable binding sites in ventricular membranes in the presence of (−)-propranolol (500 nm) and GTP (100 μm) withBmax values of 51.6 ± 8.9 fmol/mg protein (pseudo Hill coefficient = 1.16 ± 0.13,n = 5) in WT and 53.3 ± 6.4 fmol/mg protein (pseudo Hill coefficient = 0.98 ± 0.03, n = 3) in β3KO. The affinity of (−)-[3H]CGP 12177 did not differ between WT (pKD = 7.34 ± 0.04) and β3KO (pKD = 7.40 ± 0.02). These affinity estimates are slightly lower than the potency estimates for the positive chronotropic effects (Table 1) but slightly larger than the potency estimates for the inotropic effects (Fig. 1) of (−)-CGP 12177. The results suggest the existence of some spare receptor capacity for this agonist in sinoatrial node but not in left atrium. Binding of (−)-[3H]CGP 12177 (55–57 nm) to ventricular putative β4-adrenoceptors in the presence of (−)-propranolol (500 nm) and GTP (100 μm) was inhibited by competing ligands to the same extent in WT and β3KO. The percentage binding inhibition in WT and β3KO, respectively, was as follows (n = 3–6): with 200 nm (−)-CGP 12177, 60.6 ± 7.6 and 79.0 ± 9.7; with 200 μm (−)-isoproterenol, 63.7 ± 5.6 and 52.6 ± 10.8; and with 1 μm (−)-bupranolol, 75.5 ± 7.2 and 57.0 ± 9.7. The differences between WT and β3KO were not statistically significant. These data are consistent with the β4-adrenoceptor nature of the saturable (−)-[3H]CGP 12177 binding site. These binding inhibition data agree with previous affinity estimates for the putative β4-adrenoceptor, obtained in rat atria from the corresponding binding inhibition curves of the three competing ligands (Sarsero et al., 1998).

    Figure 7
    View larger version:
    Figure 7

    Saturability of the putative β4-adrenoceptor. Individual saturation binding experiments show specific binding of (−)-[3H]CGP 12177 (1–200 nm) to mouse ventricular membranes: a, Membranes prepared from β3KO. b, Membranes prepared from WT. Binding of (−)-[3H]CGP 12177 was performed in the presence of 500 nm (−)-propranolol to block β1- and β2-adrenoceptors and nonspecific binding was determined with 20 μm (−)-CGP 12177.

    Expression of the putative β4-adrenoceptor may not be restricted to cardiac tissues. The β4-adrenoceptor may coexist and cofunction with β3-adrenoceptors. This may be the case for lipolysis in rat adipocytes (Galitzky et al., 1997) and relaxation in rat colon (Kaumann and Molenaar, 1996). In both systems the agonist effects of CGP 12177 were only blocked with low potency, whereas the effects of β3-adrenoceptor agonists were blocked with high potency by the β3-adrenoceptor-selective antagonist SR 59230A. The SR 59230A-resistant component of the CGP 12177 responses that are blocked by bupranolol in both adipocytes and colon could be mediated through the putative β4-adrenoceptor.

    We conclude that (−)-CGP 12177 causes similar cardiostimulant effects in atria from both WT and β3KO mice. The ventricular putative β4-adrenoceptors are expressed at the same density and possess the same affinity for (−)-[3H]CGP 12177 in WT and β3KO. Our results demonstrate that the cardiostimulant effects of (−)-CGP 12177 are mediated through the putative β4-adrenoceptor, which is not a splice variant of the β3-adrenoceptor and hence may be encoded by a distinct gene. Our results rule out the invoked possibility of tissue-dependent differences of G protein-coupling of β3-adrenoceptor to account for the cardiostimulant effects of (−)-CGP 12177 and support mediation through a different receptor (i.e., the putative β4-adrenoceptor). However, both the β3-adrenoceptor and putative β4-adrenoceptor mediate agonist effects of (−)-CGP 12177 that are resistant to blockade by (−)-propranolol but blocked by (−)-bupranolol.

    Previous SectionNext Section

    Footnotes

    • Send reprint requests to: Dr. A. J. Kaumann, The Babraham Institute, Cambridge CB2 4AT, England. E-mail:alberto.kaumann{at}bbsrc.ac.uk

    • This work was supported by the British Heart Foundation (A.J.K.) and by a Senior Research Fellowship (P.M.) at the National Health and Medical Research Council of Australia.

    • Abbreviations:
      (−)-CGP 12177
      (−)-4–3(tertiarybutylamino-2-hydroxypropoxy)benzimidazol-2-one hydrochloride
      BAT
      brown adipose tissue
      β3KO
      β3-adrenoceptor knockout
      IBMX
      3-isobutyl-1-methylxanthine
      kb
      kilobase pair(s)
      WT
      wild-type
      EGTA
      ethylene glycol bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
      • Received December 11, 1997.
      • Accepted January 12, 1998.
    Previous Section
     

    References

    1. ↵
      1. Arch JRS
      (1997) β3-adrenoceptors and other putative β-adrenoceptors. Pharmacol Res Commun 9:141–148.
    2. ↵
      1. Arch JRS,
      2. Kaumann AJ
      (1993) β3- and atypical β-adrenoceptors. Med Res Rev 14:663–729.
    3. ↵
      1. Berkowitz DE,
      2. Nardone NA,
      3. Smiley RM,
      4. Price DT,
      5. Kreutter DK,
      6. Fremeau RT,
      7. Schwinn B
      (1995) Distribution of β3-adrenoceptor mRNA in human tissues. Eur J Pharmacol 289:223–228.
      CrossRefMedlineWeb of Science
    4. ↵
      1. Blin N,
      2. Nahmias C,
      3. Brumare MF,
      4. Strosberg AD
      (1994) Mediation of most atypical effects by species homologues of the β3-adrenoceptor. Br J Pharmacol 112:911–919.
      MedlineWeb of Science
    5. ↵
      1. Blinks JR
      (1965) Convenient apparatus for recording contractions of isolated muscle. J Appl Physiol 20:755–757.
      Abstract/FREE Full Text
    6. ↵
      1. Galitzky J,
      2. Languin D,
      3. Verwaerde P,
      4. Montastruc J-L,
      5. Lafontan M,
      6. Berlan M
      (1997) Lipolytic effects of conventional β3-adrenoceptor agonists and of CGP 12177 in rat and human fat cells: preliminary pharmacological evidence for a putative β4-adrenoceptor. Br J Pharmacol 122:1244–1250.
      CrossRefMedlineWeb of Science
    7. ↵
      1. Gauthier C,
      2. Tavernier G,
      3. Charpentier F,
      4. Languin D,
      5. Le Marec H
      (1996) Functional β3-adrenoceptors in the human heart. J Clin Invest 98:556–562.
      MedlineWeb of Science
    8. ↵
      1. Giacobino JP
      (1995) β3-adrenoceptor: an update. Eur J Endocrinology 132:377–385.
      Abstract/FREE Full Text
    9. ↵
      1. Granneman JG,
      2. Lahners KN,
      3. Chaudhry A
      (1991) Molecular cloning and expression of the rat β3-adrenergic receptor. Mol Pharmacol 40:895–899.
      Abstract
    10. ↵
      1. Granneman JG,
      2. Lahners KN,
      3. Chaudhry A
      (1993) Characterization of the human β3-adrenergic receptor gene. Mol Pharmacol 44:264–270.
      Abstract
    11. ↵
      1. Harding S
      (1997) Lack of evidence for β3-adrenoceptor modulation of contractile function in human ventricular myocytes. Circulation 96:I-53.
    12. ↵
      1. Kaumann AJ
      (1989) Is there a third heart β-adrenoceptor? Trends Pharm Sci 10:316–320.
      Medline
    13. ↵
      1. Kaumann A J
      (1990) Piglet sinoatrial 5-HT receptors resemble human atrial 5-HT4-like receptors. Naunyn-Schmiedebergs Arch Pharmacol 342:619–622.
      MedlineWeb of Science
    14. ↵
      1. Kaumann AJ
      (1996) (−)-CGP 12177-induced increase of human atrial contraction through a putative third β-adrenoceptor. Br J Pharmacol 117:619–622.
      MedlineWeb of Science
    15. ↵
      1. Kaumann AJ
      (1997) Four β-adrenoceptor subtypes in mammalian heart. Trends Pharmacol Sci 18:70–76.
      CrossRefMedline
    16. ↵
      1. Kaumann AJ,
      2. Lynham JA
      (1997) (−)-CGP 12177 stimulates cyclic AMP-dependent protein kinase in rat atria through an atypical β-adrenoceptor. Br J Pharmacol 120:1187–1189.
      CrossRefMedlineWeb of Science
    17. ↵
      1. Kaumann AJ,
      2. Lynham JA,
      3. Sarsero D,
      4. Molenaar P
      (1997) The atypical cardiostimulant β-adrenoceptor is distinct from β3-adrenoceptors and is coupled to a cyclic AMP-dependent pathway in rat and human myocardium. Br J Pharmacol 120:102P.
      CrossRef
    18. ↵
      1. Kaumann AJ,
      2. Molenaar P
      (1996) Differences between the third cardiac β-adrenoceptor and the colonic β3-adrenoceptor in the rat. Br J Pharmacol 118:2085–2098.
      MedlineWeb of Science
    19. ↵
      1. Kaumann AJ,
      2. Molenaar P
      (1997) Modulation of human cardiac function through 4 β-adrenoceptor populations. Naunyn-Schmiedebergs Arch Pharmacol 355:667–681.
      CrossRefMedlineWeb of Science
    20. ↵
      1. Kenakin T
      (1995) Agonist receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232–238.
      CrossRefMedline
    21. ↵
      1. Krief S,
      2. Lönnqvist F,
      3. Raimbault S,
      4. Baude B,
      5. van Spronsen A,
      6. Arner P,
      7. Strosberg AD,
      8. Riquier D,
      9. Emorine LJ
      (1993) Tissue distribution of β3-adrenoceptor mRNA in man. J Clin Invest 91:344–349.
    22. ↵
      1. Langin D,
      2. Portillo MP,
      3. Saulnier-Blache J-S,
      4. Lafontan M
      (1991) Coexistence of three β-adrenoceptor subtypes in white fat cells of various mammalian species Eur J Pharmacol 199:291–301.
    23. ↵
      1. Lehrach H,
      2. Diamond D,
      3. Wozney JM,
      4. Boedtker H
      (1977) RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination. Biochemistry 16:4743–4751.
      CrossRefMedline
    24. ↵
      1. Lelias M,
      2. Kaghad M,
      3. Rodriguez M,
      4. Chalon P,
      5. Bonnin J,
      6. Dupre I,
      7. Delpech B,
      8. Bensaid M,
      9. LeFur G,
      10. Ferrara P,
      11. Caput D
      (1993) Molecular cloning of a human β3-adrenergic receptor cDNA. FEBS Lett 324:127–130.
      CrossRefMedlineWeb of Science
    25. ↵
      1. Lönnqvist JG,
      2. Krief S,
      3. Strosberg AD,
      4. Nyberg B,
      5. Emorine LJ,
      6. Arner P
      (1993) Evidence for a functional β3-adrenoceptor in man. Br J Pharmacol 110:929–936.
      MedlineWeb of Science
    26. ↵
      1. Lowry OH,
      2. Rosebrough NJ,
      3. Farr AL,
      4. Randall RJ
      (1951) Protein measurement with folin reagent. J Biol Chem 193:265–275.
      FREE Full Text
    27. ↵
      1. Malinowska B,
      2. Schlicker E
      (1996) Atypical β-adrenoceptors, different from β3-adrenoceptors, mediate the positive chronotropic effects of CGP 12177 and cyanopindolol in the pithed rat. Br J Pharmacol 117:943–949.
      MedlineWeb of Science
    28. ↵
      1. Molenaar P,
      2. Sarsero D,
      3. Arch JRS,
      4. Kelly J,
      5. Henson SM,
      6. Kaumann AJ
      (1997a) Effects of (−)-RO363 at human atrial β-adrenoceptor subtypes, the human cloned β3-adrenoceptor and rodent intestinal β3-adrenoceptors. Br J Pharmacol 120:165–176.
      CrossRefMedlineWeb of Science
    29. ↵
      1. Molenaar P,
      2. Sarsero D,
      3. Kaumann AJ
      (1997b) Proposal for the interaction of nonconventional partial agonists and catecholamines with the putative β4-adrenoceptor in mammalian heart. Clin Exp Pharmacol Physiol 24:647–656.
      MedlineWeb of Science
    30. ↵
      1. Revelli JP,
      2. Muzzin P,
      3. Giacobino JP
      (1992) Modulation in vivo of β-adrenergic-receptor subtypes in rat brown adipose tissue by the thermogenic agonist Ro 16–8714. Biochem J 286:743–746.
    31. ↵
      1. Revelli JP,
      2. Preitner F,
      3. Samec S,
      4. Muniesa P,
      5. Kuehne F,
      6. Boss O,
      7. Vassalli JD,
      8. Dulloo A,
      9. Seydoux J,
      10. Giacobino JP,
      11. Huarte J,
      12. Ody C
      (1997) Targeted gene disruption reveals a leptin-independent role for the mouse β3-adrenoceptor in the regulation of body composition. J Clin Invest 100:1098–1106.
      MedlineWeb of Science
    32. ↵
      1. Sarsero D,
      2. Molenaar P,
      3. Kaumann AJ
      (1996) The human cardiac atypical β-adrenoceptor stimulates a cyclic AMP-dependent pathway. J Mol Cell Cardiol 28:A274.
    33. ↵
      1. Sarsero D,
      2. Molenaar P,
      3. Kaumann AJ
      (1997) Validity of (−)-[3H]-CGP 12177A as a radioligand for the ‘putative β4-adrenoceptor’ in rat atrium (abstract). Pharmacologist 39:39.
    34. ↵
      1. Sarsero D,
      2. Molenaar P,
      3. Lynham JA,
      4. Kaumann AJ
      (1998b) The putative β4-adrenoceptor mediates positive inotropic responses and hastens relaxation through a cAMP pathway in human heart (abstract). Aust NZ J Med 28:147.
    35. ↵
      1. Sarsero D,
      2. Molenaar P,
      3. Kaumann AJ
      (1998a) Validity of (−)-[3H]CGP 12177 as a radioligand for the ‘putative β4 adrenoceptor’ in rat atrium. Br J Pharmacol 123:371–380.
    36. ↵
      1. Strosberg AD,
      2. Pietri-Rouxel F
      (1996) Function and regulation of the β3-adrenoceptor. Trends Pharmacol Sci 17:373–381.
      Medline
    37. ↵
      1. Susulic VS,
      2. Frederich RC,
      3. Lawitts J,
      4. Tozzo E,
      5. Kahn BB,
      6. Harper M-E,
      7. Himms-Hagen J,
      8. Flier JS,
      9. Lowell BB
      (1995) Targeted disruption of the β3-adrenergic receptor gene. J Biol Chem 270:29483–29492.
      Abstract/FREE Full Text
    38. ↵
      1. Walter M,
      2. Lemoine H,
      3. Kaumann AJ
      (1984) Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of β-adrenoceptor subtypes in the dissociation between blockade and stimulation. Naunyn-Schmiedebergs Arch Pharmacol 327:159–175.
      CrossRefMedline
    39. ↵
      1. Wheeldon NM,
      2. McDevitt DG,
      3. Lipworth BJ
      (1993) Investigation of putative cardiac β3-adrenoceptors in man. Q J Med 86:255–261.
      Abstract/FREE Full Text
    « Previous | Next Article »Table of Contents

    This Article

    1. Molecular Pharmacology April 1, 1998 vol. 53 no. 4 670-675
    1. AbstractFree
    2. » Full Text
    3. Full Text (PDF)

    Classifications

    Responses

    1. Submit a response
    2. No responses published

    Navigate This Article

    Current Issue

    1. November 2009, 76 (5)
    1. Current Issue
    1. Alert me to new issues of Molecular Pharmacology